Gauri Arora, | |
1455 Dixon Ave, Lafayette, CO 80026-8879 | |
(303) 443-8500 | |
Not Available |
Full Name | Gauri Arora |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 1455 Dixon Ave, Lafayette, Colorado |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013687292 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Gauri Arora, 1455 Dixon Ave, Lafayette, CO 80026-8879 Ph: (303) 443-8500 | Gauri Arora, 1455 Dixon Ave, Lafayette, CO 80026-8879 Ph: (303) 443-8500 |
News Archive
Chronic liver diseases rank as the 12th cause of death worldwide and many of these disorders are associated with unhealthy lifestyles. Conversely, a healthier lifestyle can help prevent or reverse liver disease.
A team of researchers at Baylor College of Medicine, the Texas Heart Institute and Texas Children's Hospital has developed a powerful new approach to understand the formation of new neurons in the mammalian adult brain.
Diabetes researchers at Sweden's Karolinska Institutet have developed a novel technique that makes it possible to monitor insulin resistance in a non-invasive manner over time in mice. The new method, presented in the journal Scientific Reports, can be used to assess insulin resistance during progression and intervention of metabolic diseases.
Seventh Wave Laboratories, a consulting-based contract research organization that assesses the safety and efficacy of pharmaceutical products and medical devices, has announced an exclusive collaboration with Yecuris Corporation, a global leader in the development and use of humanized models in drug development research.
New research shows that nearly three-quarters of patients with moderate to severe ulcerative colitis (UC) taking conventional treatments describe their disease as ‘poorly controlled' (continuous or regular experience of symptoms that negatively affect quality of life), with half saying they are somewhat or completely dissatisfied with their current medication; only 1% were completely satisfied with their current treatment.
› Verified 7 days ago